Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.

Tae Won YiBrendan SmythGian Luca Di TannaClare ArnottKathryn CardozaAmy KangCarol PollockRajiv AgarwalGeorge BakrisDavid M CharytanDick de ZeeuwHiddo J L HeerspinkBruce NealDavid C WheelerChristopher P CannonHong ZhangBernard ZinmanVlado PerkovicAdeera LevinKenneth W MahaffeyMeg Jardinenull null

Published in: American journal of kidney diseases : the official journal of the National Kidney Foundation (2023)

Canagliflozin consistently reduced the relative risk of kidney events in people with diabetic kidney disease in both sexes and across age subgroups. Owing to higher background risk, the absolute reduction in adverse kidney outcomes was greater in younger participants.

Keyphrases

type diabetes
skeletal muscle
double blind
insulin resistance
weight loss
breast cancer risk